All Pharma News
price-trendAsk Us
OrsoBio Presents Phase 1 and Preclinical Data at ADA 84th Sessions

OrsoBio Presents Phase 1 and Preclinical Data at ADA 84th Sessions
BUSINESSWIRE
21 Jun 2024
Share Share
Lilly backs OrsoBio`s $60M Series A for PhII trials in obesity and NASH

Lilly backs OrsoBio`s $60M Series A for PhII trials in obesity and NASH
Kyle LaHucik ENDPTS
08 Nov 2023
Share Share
OrsoBio Announces $60M Series A Financing

OrsoBio Announces $60M Series A Financing
BUSINESSWIRE
07 Nov 2023
Share Share
OrsoBio to Present Phase 1 Data for Liver-Targeted LXR Inverse Agonist TLC-2716

OrsoBio to Present Phase 1 Data for Liver-Targeted LXR Inverse Agonist TLC-2716
BUSINESSWIRE
06 Nov 2023
Share Share
OrsoBio to Present Phase 1 Data for the TLC-6740

OrsoBio to Present Phase 1 Data for the TLC-6740
BUSINESSWIRE
16 Oct 2023
Share Share
OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore

OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore
BUSINESSWIRE
05 Jun 2023
Share Share
OrsoBio Announces First Patient Dosed in Phase 2 Trial of TLC-3595

OrsoBio Announces First Patient Dosed in Phase 2 Trial of TLC-3595
BUSINESSWIRE
20 Mar 2023
Share Share
OrsoBio Launches to Develop Novel Therapies for Severe Metabolic Disorders

OrsoBio Launches to Develop Novel Therapies for Severe Metabolic Disorders
BUSINESSWIRE
01 Nov 2022
Share Share